You are currently viewing Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist to the NASDAQ.

Eric Weisblum, CEO, stated “Silo Pharma is proud to announce that we intend to begin the application process to list on the NASDAQ exchange. Uplisting to The NASDAQ Capital Market is an important milestone at Silo Pharma as we continue to execute on our initiatives to build long term shareholder value. The prospective uplisting will increase our visibility in the marketplace as well as expand our institutional shareholder base.”

The listing of the Company’s common shares on a national exchange is subject to exchange approval and the ability of the Company to satisfy all applicable listing and regulatory requirements. While the Company intends to satisfy all of the applicable listing criteria, there is no assurance that a national exchange will approve the Company’s application or that the Company will complete the listing as proposed.

About Silo Pharma 
Silo Pharma. Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact: 
Hayden IR 
Brett Maas 
646-536-7331 
Email: brett@haydenir.com